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Dan Wang1†, Bijaya Upadhyaya1†, Yi Liu1†, David Knudsen2 and Moul Dey1*Abstract
Background: The cytokine TRAIL (tumor necrotic factor-related apoptosis-inducing ligand) selectively induces apoptosis
in cancer cells, but cancer stem cells (CSCs) that contribute to cancer-recurrence are frequently TRAIL-resistant. Here we
examined hitherto unknown effects of the dietary anti-carcinogenic compound phenethyl isothiocyanate (PEITC) on
attenuation of proliferation and tumorigenicity and on up regulation of death receptors and apoptosis in human
cervical CSC.
Methods: Cancer stem-like cells were enriched from human cervical HeLa cell line by sphere-culture method and
were characterized by CSC-specific markers’ analyses (flow cytometry) and Hoechst staining. Cell proliferation assays,
immunoblotting, and flow cytometry were used to assess anti-proliferative as well as pro-apoptotic effects of PEITC
exposure in HeLa CSCs (hCSCs). Xenotransplantation study in a non-obese diabetic, severe combined immunodeficient
(NOD/SCID) mouse model, histopathology, and ELISA techniques were further utilized to validate our results in vivo.
Results: PEITC attenuated proliferation of CD44high/+/CD24low/–, stem-like, sphere-forming subpopulations of hCSCs in
a concentration- and time-dependent manner that was comparable to the CSC antagonist salinomycin. PEITC
exposure-associated up-regulation of cPARP (apoptosis-associated cleaved poly [ADP-ribose] polymerase) levels
and induction of DR4 and DR5 (death receptor 4 and 5) of TRAIL signaling were observed. Xenotransplantation
of hCSCs into mice resulted in greater tumorigenicity than HeLa cells, which was diminished along with serum
hVEGF-A (human vascular endothelial growth factor A) levels in the PEITC-pretreated hCSC group. Lung metastasis was
observed only in the hCSC-injected group that did not receive PEITC-pretreatment.
Conclusions: The anti-proliferative effects of PEITC in hCSCs may at least partially result from up regulation of
DR4 and possibly DR5 of TRAIL-mediated apoptotic pathways. PEITC may offer a novel approach for improving
therapeutic outcomes in cancer patients.
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Despite considerable improvement in cancer diagnosis
and therapy, relapse and metastasis are still common [1].
However, the rise of the cancer stem cell (CSC) hypoth-
esis provides a new approach to eradicating malignan-
cies. Recent studies have shown that CSCs are a small
subpopulation of tumor cells that possess self-renewal
and tumor-initiation capacity and the ability to give rise* Correspondence: Moul.Dey@sdstate.edu
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unless otherwise stated.to the heterogeneous lineages of malignant cells that
comprise a tumor [2]. CSCs have been identified in
hematologic and solid cancers and implicated in tumor
initiation, development, metastasis, and recurrence.
Although the origin(s) and dynamic heterogeneity of
CSCs remain unexplained, designing novel approaches
to target CSCs has received much attention over the
past several years [3-5].
Phenethyl isothiocyanate (PEITC) is a dietary com-
pound derived from common vegetables such as water-
cress, broccoli, cabbage, and cauliflower [6]. We and
others have shown under experimental conditions thattd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ventive activity against various cancers, including colon
[9], prostate [10], breast [11], cervical [12,13], ovarian
[14], and pancreatic cancer [15]. Safety studies in rats
and dogs have shown that PEITC has no apparent tox-
icity, even when administered in high doses, as deter-
mined by NOEL (no-observed-adverse-effect-level) [16],
and PEITC is currently in clinical trials in the US for
lung cancer (NCT00691132). Cervical cancer is the
second-most-fatal cancer in women worldwide, and the
incidence rate is significantly higher in developing na-
tions due to the absence of rigorous screening programs
[17]. A recent study showed that PEITC can induce the
extrinsic apoptosis pathway in a human cervical cancer
cell line [12]. However, the chemotherapeutic effects of
PEITC in the context of CSCs and more specifically
cervical CSCs remain unknown.
Apoptosis, or programmed cell-death, is essential to
maintaining tissue homeostasis, and its impairment is
implicated in many human diseases, including cancers
[18]. The tumor necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL), a member of the tumor necro-
sis factor super-family, has attracted great interest for
clinical applications due to its specific anti-tumor poten-
tial without toxic side effects to normal healthy cells
[19,20]. There are two well-characterized apoptosis path-
ways in mammalian cells. The extrinsic pathway is medi-
ated by death receptors, a subgroup of the TNF receptor
superfamily. TRAIL binds to TRAIL-R1 and TRAIL-R2,
two death domain-containing receptors, also called DR4
and DR5, to trigger apoptosis. The intrinsic pathway in-
volves mitochondria, and is triggered and controlled by
members of the Bcl-2 protein family. Both pathways
cause the activation of initiator caspases, which then
activate effector caspases [21]. Caspases cause cleavage
and inactivation of poly (ADP-ribose) polymerase 1
(PARP)-1, which helps repair single-stranded DNA breaks,
and hence PARP-1 cleavage serves as a hallmark of apop-
tosis [22]. Unfortunately, a variety of human tumors
develop resistance to TRAIL-induced apoptosis [23]. But
further studies have suggested that TRAIL activity can be
sensitized with other chemotherapeutic drugs, such as
paclitaxel [24], 5-fluorouracil (5-FU) [25], and cisplatin
[26] or dietary bioactive compounds like benzyl isothio-
cyanate (BITC) [27] or sulforaphane [28,29]. However, the
effects of PEITC on TRAIL pathway in CSCs have not
been reported.
In the present study, we investigated the efficacy of
PEITC in attenuating the growth of sphere-forming cervical
CSCs isolated from HeLa cells (hCSCs) as well as its
ability to up regulate death receptors for TRAIL-
mediated induction of apoptosis. Furthermore, the
in vivo anti-tumorigenicity effects of PEITC were eval-
uated in a xenograft mouse model.Methods
Test compounds
Phenethyl isothiocyanate (Sigma-Aldrich, St. Louis, MO),
99%, was diluted in dimethyl sulfoxide (DMSO, Sigma-
Aldrich, St. Louis, MO) to make 0.5–20-mM stock
concentrations and was further diluted in media to obtain
2.5–20-μM final concentrations, which are achievable
following oral administration in human [30] and have been
used in prior studies by us and others to induce apop-
tosis in the SW480 colon cancer cell line [9] and cervical
cancer cell lines. We used comparable concentrations of
salinomycin (2.5–20 μM) and lower concentrations
(2.5–20 nM) of paclitaxel (both from Sigma-Aldrich,
St. Louis, MO) as positive controls, which are CSC-
targeted and CSC-non-specific anti-cancer chemother-
apeutics, respectively, following Gupta et al. [31]. For
the negative/vehicle control samples, we used DMSO
in an amount equivalent to that used with test com-
pounds in test samples.Sphere cultures of hCSCs
The human HeLa cell line (ATCC® CCL-2™, American
Type Culture Collection, Manassas, VA) was cultured
and maintained in a T-25 flask with Dulbecco’s modified
eagle’s medium (DMEM) containing 4 mM L-glutamine
and 4.5 g/L glucose (HyClone, Logan, UT), supple-
mented with 10% heat-inactivated fetal bovine serum
(Invitrogen, Grand Island, NY) and 1% penicillin (25 U/ml)/
streptomycin (25 μg/ml) (Sigma-Aldrich, St. Louis, MO)
in a 5% CO2-humidified atmosphere at 37°C. HeLa cells
were trypsinized with TrypLE (Invitrogen, Grand Island,
NY) and then sub-cultured with a 1:5 splitting ratio when
the cells reached about 90% confluency. From the parental
HeLa cells (termed simply as HeLa in the rest of the docu-
ment), hCSCs were cultured following a modified protocol
described by Gu et al. [5]. Briefly, single-cell suspensions
of HeLa cells (4 × 104) were seeded into a 100-mm ultra-
low attachment (ULA) petri dish (Corning Inc., Corning,
NY) containing 8 ml of serum-free mammary epithelial
basal medium (MEBM, Lonza, Allendale, NJ), supple-
mented with 1× B27 (Invitrogen, Grand Island, NY), 4 μg/
ml heparin (Sigma-Aldrich, St. Louis, MO), 20 ng/ml
hEGF, and 20 ng/ml hFGF (Invitrogen, Grand Island, NY).
After an initial 4-day culture in suspension at 37°C, an
additional 9 ml of sphere culture medium was added for
another 5 days of culture. On day 9, spheres were
harvested by centrifugation at 500 × g for 3 minutes,
followed by washing with phosphate-buffered saline
(PBS), trypsinization with TrypLE for 10 minutes at 37°C,
centrifugation at 500 × g for 3 minutes, resuspension in
5 ml of hCSC culture medium, and counting with a
hemocytometer. Both HeLa cells and hCSCs were used
for successive experiments.
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Around 2 × 106 HeLa cells were seeded into a 60-mm
petri dish and incubated overnight at 37°C. Cells were
washed with 2 ml of PBS, trypsinized with 1 ml of
TrypLE, and resuspended in 1 ml of PBS, followed by
immunostaining. Similarly, hCSCs were collected after
9 days of culture, trypsinized, and resuspended in 2 ml
of PBS with a density of 1 × 106 cells/ml, followed by
immunostaining. Cells were immunostained with anti-
CD24–FITC (1:500 v/v, Millipore, Billerica, MA) or
anti-CD44–FITC (1:500 v/v, Millipore, Billerica, MA)
antibodies for 1 hour at room temperature. Immuno-
fluorescence was measured using a FACSCalibur cell
analyzer (Becton Dickinson, San Jose, CA) with approxi-
mately 10,000 events in each sample. Propidium iodide/
annexin V staining was performed according to the man-
ufacturer’s instructions. Briefly, 5 × 105 cells were centri-
fuged and resuspended in 100 μl of 1x binding buffer
(Invitrogen, Grand Island, NY). The cells were treated
with 10 μM PEITC or vector control (DMSO) for a total
of 24 h, in the last hour of which 10 ng/ml of human re-
combinant TRAIL (eBioscience, Inc., San Diego, CA) or
vector control (DMEM) were added to the cells before
harvesting. The cells were then incubated with 5 μl of
annexin V–FITC (eBioscience, Inc., San Diego, CA) and
5 μl of propidium iodide (eBioscience, Inc., San Diego,
CA) at room temperature for 5 minutes in the dark be-
fore analyzing the cells on a FACSCalibur cell analyzer.
For DR4 and DR5 expression analysis, 5 × 105 cells were
filtered through a filter cap (35 μm) into a collecting
tube (BD Falcon, Franklin Lakes, NJ) and then washed,
fixed with 2% paraformaldehyde, and stained with DR4
or DR5 surface markers (1:200 v/v) overnight at 4°C in a
rotating vessel. The immunostained cells were incubated
with goat anti-mouse Dylight 488 (1:500 v/v) secondary
antibody for 2 hours at room temperature before acquir-
ing at least 10,000 cells in a flow cytometer.
Hoechst exclusion assay
The fluorescence resulting from interaction of cell DNA
with Hoechst 33342 dye was measured to assess the
cell’s ability to efflux the fluorescent dye Hoechst 33342,
as most hematopoietic stem cells are able to exclude the
dye [32]. HeLa or hCSCs were trypsinized with TrypLE,
washed with PBS, and adjusted to 1 × 106 cells/ml in
Hanks’ balanced salt solution (HBSS), before incubating
with 5 μg/ml Hoechst 33342 dye (Life Technologies,
Grand Island, NY) for 60 minutes at 37°C in a 5% CO2
incubator. The cells were then washed three times with
HBSS by centrifugation at 300 × g for 5 minutes. The pel-
lets were resuspended at 1 × 106 cells/ml in HBSS and kept
on ice until used for imaging. The Hoechst staining was
visualized with an EVOS FL Epifluorescent Microscope
(AMG, Bothell, WA) using the DAPI channel. Images wereindicated as “transmitted” (phase contrast images of whole
cells), “Hoechst-stained” (nuclei with Hoechst staining),
and “merge” (an overlay of transmitted and Hoechst stain-
ing in the same field). The cells with Hoechst-stained
nuclei were counted among 100 cells, and the number of
Hoechst-excluded cells was then quantified.
Sphere-formation assay
The hCSCs were enriched in spheres in serum-free
medium. Sphere culture was carried out as previously de-
scribed in the sphere culture section. Cells were treated
with predetermined doses of 0.5, 1.0, or 2.5 μM of PEITC
or DMSO as control. After 7 days incubation, photomicro-
graphs of spheres were acquired under an inverted phase-
contrast microscope (Olympus America Inc., Center Valley,
PA), and the number of hCSCs was counted using a
hemocytometer.
Cell proliferation assay
A standard colorimetric method (MTS assay) was used
to determine the number of viable cells in samples. For
cell-proliferation assays, HeLa and hCSCs were cultured
for 4 days, and an additional 9 ml of sphere culture
medium was added for another 5 days, as described in
the sphere culture section. Viable cells were harvested
and counted with a hemocytometer before seeding into
96-well microplates at a density of 2 × 104 cells per
well. Cells were cultured in DMEM supplemented with
100 U/ml penicillin, 100 μg/ml streptomycin, 5% heat-
inactivated FBS, and 50 μM 2-mercaptoethanol. Both
hCSCs and HeLa cells were treated with four concentra-
tions of PEITC and salinomycin (2.5–20 μM) and pacli-
taxel (2.5–20 nM). After 24 and 48 hours of incubation,
20 μl of CellTiter reagent was added directly to the cell-
culture wells and incubated for 1 hour at 37°C, followed
by cell viability assessment using the CellTiter 96 AQue-
ous One Solution Cell Proliferation Assay kit (Promega,
Madison, WI), containing [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-
zolium, inner salt; MTS]. The manufacturer’s instruc-
tions were followed, and treatments were compared with
vehicle control (DMSO-treated cells) at 490 nm in a
BioTek Synergy H4 multimode plate reader (BioTek,
Winooski, VT).
Immunoblotting
hCSCs (1 × 106) were seeded in each well of a 6-well
plate and incubated overnight at 37°C in a 5% CO2 incu-
bator. Old culture medium was replenished by culture
medium containing either 10-μM or 15-μM concentrations
of PEITC for 5 hours. The cells were then treated with
10 ng/ml human recombinant TRAIL or with 10 ng/ml
TNFα (eBioscience, Inc., San Diego, CA) for additional
1-hour incubation. Cell harvesting and immunoblotting
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were lysed in ice-cold RIPA buffer containing 150 mM
NaCl, 50 mM Tris (pH 8.0), 10% glycerol, 1% Nonidet P-40
(NP-40), and 0.4 mM EDTA, followed by a brief vortexing
and rotation for 30 minutes at 4°C. Equal amounts (v/v) of
cell lysates were separated by SDS-PAGE through a 12%
separating gel, transferred to nitrocellulose membranes,
blocked with 5% non-fat dry milk, and double-probed over-
night at 4°C with mouse anti-human cPARP (1:1000 v/v,
Millipore, Billerica, MA) and rabbit anti-human β-actin
(1:5000 v/v, Millipore, Billerica, MA) antibodies. Blots were
then washed in PBS and further incubated with secondary
antibodies, Dylight 680 anti-mouse (1:5000 v/v) and
Dylight 800 anti-rabbit (1:5000 v/v), for 1 hour at room
temperature. Finally, after rinsing in Tween20 (0.1% in
PBS), blots were imaged with a LI-COR Odyssey Infrared
Imaging System (LI-COR Biosciences, Lincoln, NE),
followed by a densitometric analysis of cPARP levels after
normalizing with the β-actin housekeeping gene.Tumorigenicity study in mice
Animal studies were carried out in accordance with the
guidelines of, and, using an approved protocol by, the
Institutional Animal Care and Use Committee (IACUC),
South Dakota State University (IACUC protocol ap-
proval #12-087A). Twenty female non-obese diabetic,
severe combined immunodeficient (NOD/SCID, NOD.
CB17-Prkdcscid/J) mice (Jackson Laboratories, Bar Har-
bor, ME), 17 weeks old, were randomly grouped into five
groups (four mice per group) in specific pathogen-free
(SPF) housing at a constant temperature of 24–26°C
with a 12-h:12-h light/dark cycle. All mice were allowed
to acclimatize for 1 week and were provided with sterile
food and water ad libitum. HeLa and hCSCs were
cultured, trypsinized, washed, pre-treated with 10 μM
PEITC where indicated, and resuspended in PBS at the
concentration of 1 × 107 cells/ml before injecting into
the mice. Each mouse was subcutaneously injected at
the neck scruff with one injection of PBS (100 μl, control
group), HeLa (1 × 106), HeLa pretreated with 10 μM
PEITC (1 × 106), hCSCs (1 × 106), or hCSCs pretreated
with 10 μM PEITC (1 × 106). The cell number in each
injection was consistent with the study previously
carried out by Gu et al. [5]. All mice were routinely
monitored for tumor formation, weight loss, pain, and
distress. The mice were euthanatized with CO2 asphyxi-
ation 21 days post-treatment, and blood was collected
through cardiac puncture immediately after sacrifice. Ex-
cised tumor and lung samples were kept in 10% formalin
for subsequent histopathological examination. The aver-
age tumor number or mass per injection was calculated
by dividing each group’s total number of tumors or total
mass by the number of mice in that group.Histopathologic examination
Excised tumor, lung, and liver were fixed by immersion
in 10% buffered formalin for 3–5 days and then trans-
ferred to 70% ethanol for long-term fixation. Representa-
tive sections of fixed tissue were trimmed and embedded
in paraffin, then sectioned at 3 μm and stained by
hematoxylin and eosin (H&E) [33] for examination per-
formed in a blind manner by a veterinary pathologist,
and photomicrographs were captured under a micro-
scope (Leica, Micro Service, St. Michael, MN) at 200×
and 400× magnification for illustrative purposes.
ELISA for serum hVEGF-A detection
Since hCSCs are of human origin, ELISA was carried
out to assess the presence of human vascular endothelial
growth factor A (hVEGF-A), which promotes tumor
angiogenesis in a host. The collected mouse blood sam-
ples were kept in a slanted position at room temperature
for 1 hour, followed by 4°C for 24 hours, and then cen-
trifuged at 5000 rpm for 5 minutes. The Platinum ELISA
kit (eBioscience, San Diego, CA) was used to quantify
the hVEGF-A present in each serum sample (pg/ml)
from a single mouse, according to the manufacturer’s
instructions.
Statistical analysis
Statistical analyses were carried out using Sigma Plot
software (Systat Software, Inc., San Jose, CA). Statistical
significance between the groups was assessed by multiple
mean comparisons using one-way analysis of variance
(ANOVA) followed by a post-hoc Dunnett’s test. Student’s t
test was applied to compare two groups receiving similar
treatments. Data were expressed as means ± SEM. Experi-
ments were repeated at least three times. The significance
of differences between means is represented by asterisks:
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
Results
In this report we used the HeLa cervical cancer cell line
to isolate and characterize hCSCs following a previously
described sphere culture method [5], which favors self-
renewal of CSCs in culture but also causes minimal
damage to the cells. In comparison with HeLa cells, the
isolated/enriched hCSC population exhibited higher
CD44 (90.93% vs. 51.52%) and lower CD24 (0.4% vs.
7.5%) cell-surface marker expression in flow cytometry
analyses (Figure 1A, B), consistent with results previ-
ously reported [5]. Multi-drug resistance characteristic
of stem cells was indicated by transporter-mediated ef-
flux of the fluorescent dye Hoechst 33342 [32], and sig-
nificantly higher numbers of Hoechst-dye-excluded cells
in hCSCs (73%) than in HeLa cells (15%) further con-
firmed their stem-like characteristics (Figure 1C, D).
Finally, in xenotransplanted mice, greater tumorigenicity
Figure 1 Identification and confirmation of isolated HeLa cancer stem cells (hCSCs). A) Representative FACS histograms showing increased
CD44 and decreased CD24 expression in hCSCs compared with HeLa cells B) Summary of FACS analyses showing the percentage of hCSCs
expressing CD44 and CD24 (n = 3) C) The Hoechst exclusion assay showing transmitted, Hoechst-stained, and overlaid images of HeLa cells and
hCSCs. Hoechst 33342 dye emits blue fluorescence when bound to dsDNA. Yellow arrows show Hoechst-excluded cells lacking dark-blue nuclei
(200-μm scale), which were typically higher in hCSCs than in HeLa cells. D) Quantification of Hoechst-dye-excluded cells showing a higher exclusion rate in
hCSCs (n = 3). E) In vivo tumorigenicity was compared in NOD/SCID mice (four animals per group) 3 weeks after xenotransplantation of HeLa cells, hCSCs,
or vehicle (naïve control), showing higher tumor counts in the hCSC group. All data are expressed as means ± SEM except for in vivo tumor counts.
Asterisks indicate statistically significant differences between the groups indicated, ***p≤ 0.001.
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the HeLa group (2 tumors/4 mice) (Figure 1E). Following
validation of hCSC characteristics, we investigated the ef-
fects of PEITC and other compounds on hCSCs. The sig-
nificance of any treatment was compared with untreated/
vehicle (DMSO) controls or otherwise specified.PEITC is cytotoxic to HeLa cells and hCSCs
PEITC attenuated the formation of primary hCSC
spheres in a concentration-dependent manner (Figure 2A).
Addition of PEITC (1.0 and 2.5 μM) resulted in a 48% and
60% decline in cell numbers, respectively (Figure 2B), which
is consistent with the corresponding reduction in sphere
Figure 2 Effects of PEITC on HeLa cell and hCSC viability. A) Representative micrographs showing PEITC-attenuated sphere formation in
hCSCs isolated from HeLa cells in a concentration-dependent manner as observed after 7 days of culture in enrichment medium (400-μm scale).
B) Histogram showing quantification of viable cells on the 7th day of sphere culture from groups shown in A (n = 5). C) Concentration-dependent
effects of PEITC on the viability of HeLa cells and hCSCs after 24 (i) and 48 (ii) hours. Salinomycin and paclitaxel were used as known
reference chemotherapeutic compounds. Absorbance was read at 490 nm, and data were expressed as percentage cell viability (n = 6).
The dotted lines represent the baseline cell viability for DMSO/naïve controls, to which all the readings were compared to obtain statistical
significance. All data represent means ± SEM, and significance was determined by comparing with naïve control or as indicated, *p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001.
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(≤2.5 μM) were used in sphere-forming enrichment
culture media than in specific assays (≥2.5 μM), as
shown in the remaining figures. PEITC also signifi-
cantly reduced proliferation of both HeLa cells and
hCSCs in a concentration-dependent manner after 24-
and 48-hour exposures, which was a pattern compar-
able to the effects of salinomycin. The observed effects
of 10 nM paclitaxel was limited (Figure 2C) in our ex-
periments, which may be due to the slow induction of
cell death after low concentrations (≤10 nM) of pacli-
taxel, which occurs up to 72 hours post treatment. It
was previously shown that low concentrations of pacli-
taxel strongly block mitosis at the metaphase/anaphase
transition but could be insufficient to cause immediate
cell death in HeLa cells [34].PEITC may sensitize the TRAIL-induced, caspase-dependent
apoptosis pathway
To investigate a potential pro-apoptotic effect of PEITC
in triggering hCSC growth inhibition, we carried out
western blot experiments on hCSCs treated with differ-
ent doses of PEITC in the presence or absence of TRAIL
and TNFα. We observed an increased expression of
cPARP with higher doses of PEITC (15 μM) following
exposure for 5 hours, which was further augmented by
the presence of 10 ng/ml TRAIL, which indicated ele-
vated levels of endogenous caspase-mediated apoptosis
in hCSCs (Figure 3A). After normalizing to the house-
keeping gene β-actin, densitometric analysis of cPARP
levels showed that PEITC induced cPARP and sensitized
the TRAIL pathway but not the TNFα pathway in hCSCs
(Figure 3A). It was previously shown that PEITC induces
Figure 3 PEITC sensitizes the TRAIL pathway in hCSC apoptosis. A) Representative immunoblot and densitometric analysis (n = 3) of cPARP
levels in hCSCs after concentration- dependent PEITC exposure in the presence/absence of TRAIL (10 ng/ml) and TNFα (10 ng/ml), normalized to
housekeeping β-actin expression levels. PEITC independently induced as well as synergized TRAIL induction of cPARP in hCSCs. B) A quantitative
bar graph illustrating individual effects as well as synergism between 10 μM PEITC and TRAIL (10 ng/ml) in sensitizing TRAIL-mediated apoptosis
(n = 3). C) Representative FACS scatter plots of data shown in B with annexin V–FITC/propidium iodide staining, confirming individual effects as
well as synergism between PEITC (10 μM) and TRAIL (10 ng/ml) in sensitizing TRAIL- mediated apoptosis (i–iv). All data represent means ± SEM,
and significance was determined by comparing with naïve control or as indicated, *p≤ 0.05, **p ≤ 0.01, ***p≤ 0.001.
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not shown). Next, we carried out an annexin V/propi-
dium iodide (PI) staining with or without TRAIL induc-
tion. Dot plot analyses showed that the fraction of
annexin-positive cells in hCSCs treated with PEITC was
higher than in untreated hCSCs (5.76% vs. 4.12%,
Figure 3B, C). Similarly, TRAIL-induced hCSCs treated
with PEITC showed increased apoptosis relative to
TRAIL-induced hCSCs (6.42% vs. 5.81%, Figure 3B, C),
although the difference was not statistically significant.
When compared with the DMSO control, both PEITC-
and TRAIL-treated hCSCs showed a trend toward higher
apoptotic levels, indicating a potential sensitization of
TRAIL-mediated apoptotic pathways by PEITC.PEITC upregulates DR4 and DR5 in the extrinsic apoptosis
pathway in hCSCs
To further understand the characteristics of PEITC in the
extrinsic apoptosis pathway in hCSCs, we carried out flow
cytometry analyses of DR4 and DR5 death receptors. Since
both PEITC- and DMSO-treated hCSCs were treated with
TRAIL (all treatments included TRAIL), we expected to
see greater induction of DR4 and DR5 in PEITC+TRAIL-
treated cells compared to TRAIL treatment alone. We
observed that PEITC induced overexpression of DR4 in
comparison with the DMSO control (69.01% and 52.52%,
Figure 4A i–ii, B). Similarly but to a lesser extent, the ex-
pression of DR5 in PEITC-treated hCSCs was higher
(72.63% and 60.57%) than in the corresponding DMSO
Figure 4 PEITC up-regulated DR4 and DR5 receptors in TRAIL signaling. A) Representative FACS histograms of DR4 and DR5 expression in
hCSCs treated with or without 10 μM PEITC in the presence of TRAIL. PEITC induced overexpression of DR4 (ii) and DR5 (iv) in comparison
with DMSO controls (i) and (iii), respectively. The histograms do not show isotype controls. B) Quantitative bar diagrams presenting the groups from
A (n = 3). All data represent means ± SEM, and significance was determined by comparing with naïve control as indicated: **p≤ 0.01, ***p≤ 0.001.
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creased overexpression of DR5 was due to PEITC treat-
ment. PEITC was previously shown to upregulate DR4 and
DR5 in a different cervical cancer cell line (HEp-2) [12];
hence, we investigated its effect only on hCSCs.
PEITC reduces the tumorigenic capacity of hCSCs
To confirm the higher tumorigenic potential of hCSCs
in vivo, we carried out a xenotransplant experiment in
NOD-SCID immunodeficient mice that included four
treatment groups and a negative/naive control group.
Tumor development did not alter food intake and over-
all well-being of the mice, as evidenced by their normal
body weight and activity (data not shown). An equal
number of cells (1× 106) containing either HeLa cells or
hCSCs (each with or without 10 μM PEITC pre-treatment)
developed different tumor loads in each group of NOD/
SCID mice. The average tumor number per injection was
observed to be much higher in the hCSC group (1.75) than
in the HeLa group (0.5), while PEITC pre-treatment helped
lower tumor formation in both hCSC (1.75 vs. 0.5) and
HeLa (0.5 vs. 0.33) groups of mice than in controls
(Figure 5B). A similar trend was observed when we cal-
culated tumor mass per injection in each group. The
hCSC group had a higher average tumor mass than the
HeLa group (95 mg vs. 60 mg, respectively, data not
shown). As expected, PEITC-treated hCSCs and HeLa
cells produced a lower mass (85 mg and 40 mg, respect-
ively) than their controls (95 mg and 60 mg, respect-
ively, data not shown). To further visualize histologicaldifferences between tumors driven by CSCs and HeLa
cells, the excised tumors were sectioned and stained
with H&E. We observed a higher number of differenti-
ated tumor cells with a low mitotic index in the HeLa
group (Figure 5Ai). By contrast, the presence of pleo-
morphic and highly proliferative cells and early signs of
neovascularization in the CSC group suggested that the tu-
mors driven by CSCs are highly aggressive (Figure 5Aiii).
On the other hand, there were more apoptotic cells in the
case of HeLa cells treated with PEITC (Figure 5Aii) and
hCSCs treated with PEITC (Figure 5Aiv), suggesting that
PEITC induces apoptosis in both HeLa cells and hCSCs.
To validate the human origin of these tumors, we per-
formed ELISA on isolated serum samples. The hCSC
group had the highest concentration of human hVEGF-
A (12.31 pg/ml), followed by hCSCs treated with PEITC
(i.e., 4.62 pg/ml) and untreated HeLa cells (1.08 pg/ml),
while we did not detect any hVEGF-A in HeLa cells
treated with PEITC (Figure 5C). To see whether hCSCs
have metastatic potential, we carried out H&E staining
of lung sections, which revealed invading tumor cells in
the lungs of the hCSC group (Figure 5D and Eiii) but
not in the other groups. Overall, hCSCs were more
tumorigenic than HeLa cells in this model, and their
tumorigenicity was attenuated by PEITC pre-treatment
prior to xenotransplant.
Discussion
Cervical cancer is the second-most-frequent female ma-
lignancy worldwide [17]. Concurrent chemoradiotherapy
Figure 5 (See legend on next page.)
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Figure 5 Effects of 10 μM PEITC-treated compared with untreated HeLa cells and hCSCs in a xenotransplant NOD/SCID mouse model.
A) Representative photomicrographs of H&E-stained and sectioned tumors (3 μm, 400x) showing greater and more aggressive tumorigenic effects
of hCSCs (iii) than HeLa cells (i). Details of native HeLa cells within a small tumor nodule with fairly uniform cell size and shape are shown (ii), and
details of a small tumor nodule showing widespread apoptosis are also shown (iv). Empty arrows indicate apoptotic cells (yellow), high mitotic
activity (blue), and early signs of neovascularization (white). B) Average tumor number per injection, where the untreated hCSC group showed
the highest number of tumors per injection. C) The highest concentration of human serum VEGF-A was in the hCSC group, indicating the human
origin of the tumors that were translocated into the blood circulation. D) The metastatic potential among the groups is shown. Metastasis was
observed only in the untreated hCSC group. E) Representative photomicrographs of H&E-stained and sectioned lungs (3 μm, 200x). Filled arrows
indicate lung bronchiole (yellow) as a landmark of distant tumor location and invading tumor cells (white) (iii). Overall, hCSCs showed increased
tumorigenic activity compared with HeLa cells in this model, which was, however, attenuated upon pre-treatment with PEITC.
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stage cervical cancer, while radical surgery and radiotherapy
are widely used for treating early-stage disease. However,
the poor control of micrometastases, declining operability,
and the high incidence of long-term complications due
to radiotherapy underscore the necessity for developing
different therapeutic approaches, such as using an adjuvant
CAM (complementary and alternative medicine) regimen
for improved treatment outcomes [35]. Among cancer pa-
tients, the use of alternative treatments ranges between 30
and 75% worldwide and frequently includes dietary ap-
proaches, herbals, and other natural products [36]. It is be-
coming increasingly evident that cancer treatment that fails
to eliminate CSCs allows relapse of the tumor [37]. Here
we report novel effects of PEITC, a phytochemical that can
be derived from a plant-based diet or may be developed as
a natural product, in attenuating in vitro hCSC proliferation
and in vivo tumorigenicity as well as stimulating intracellu-
lar receptors that mediate TRAIL-induced apoptosis.
According to the CSC concept of carcinogenesis, CSCs
represent novel and translationally relevant targets for
cancer therapy, and the identification, development, and
therapeutic use of compounds that selectively target
CSCs are major challenges for future cancer treatment
[37]. It is proposed that direct targeting of CSCs through
their defining surface antigens, such as CD44, is not a
rational option, because these antigens are frequently
expressed on normal stem cells [38]. On the other hand,
triggering tumor cell apoptosis, in general, is the founda-
tion of many cancer therapies. In the case of CSCs, it
was suggested that the induction of apoptosis in the
CSC fraction of tumor cells by specifically upregulating
death receptors or death receptor ligands such as TRAIL
is a potential strategy to bypass the refractory response
of CSCs to conventional therapies [38]. Preclinical stud-
ies have demonstrated the potential of TRAIL to select-
ively induce apoptosis of tumor cells, because normal
cells possess highly expressed decoy receptors that pro-
tect them from cell death [20,39], which has driven the
development of TRAIL-based cancer therapies [38,40].
Unfortunately, a considerable range of cancer cells, es-
pecially in some highly malignant tumors, are resistant
to TRAIL-induced apoptosis [41]. Therefore, TRAILsynergism using PEITC, a compound with an estab-
lished low-toxicity profile in healthy animals [16] could
offer an important approach to overcoming the current
challenges in using TRAIL-targeted therapies, particu-
larly in otherwise-resistant CSCs.
PEITC treatment in hCSCs reduced proliferation and
sphere formation and expressed higher levels of cPARP,
indicating elevated levels of apoptosis, which is possibly
through caspase activation by isothiocyanate in treated
cancer cells as reported previously [42]. At similar micro-
molar concentrations, the effects of PEITC on hCSC prolif-
eration were comparable to salinomycin, which was shown
to effectively eliminate CSCs and to induce partial clinical
regression of heavily pretreated and therapy-resistant can-
cers [37]. It is worth mentioning here that salinomycin had
considerable cytotoxicity in healthy mammals [37]. PEITC
has been well documented for safety to normal mammals.
It is interesting to investigate if PEITC is cytotoxic to nor-
mal stem cells, which has not been reported. Moreover, the
effects of PEITC were significantly better in abrogating
hCSC proliferation than paclitaxel, a current cancer chemo-
therapeutics. This better anti-proliferative effect may be
due to the high level of chemoresistance of CSCs to pacli-
taxel, the overcoming of which by specific targeting of
CSCs is hailed as critical. The concentration range of
PEITC used (2.5–20 μM) was validated in our previous
studies [8,9,43] and was also shown to be achievable follow-
ing oral administration in human [30].
We observed that PEITC likely sensitized TRAIL but
not the TNFα pathway while inducing apoptosis. Al-
though TNF-α can trigger apoptosis in some solid tu-
mors, its clinical usage has been limited by the risk of
lethal systemic inflammation [44]. By comparing hCSCs
treated with PEITC to those without PEITC, we ob-
served PEITC also induced the expression of death re-
ceptors DR4 and DR5 in hCSCs, which has not been
reported earlier. PEITC was, however, previously shown
to upregulate DR4 and DR5 in a different human cer-
vical cancer cell line [12]. The expression levels of either
DR4 alone or both death receptors are correlated with
TRAIL sensitivity of a cell line [45]. Our result revealed
expression of both death receptors were elicited follow-
ing PEITC treatment, but DR5 expression increase was
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is known to trigger apoptosis through binding to DR4 or
DR5, which contain cytoplasmic death domains responsible
for recruiting adaptor molecules involved in caspase activa-
tion [21]. Since all treatments shown in Figure 4 included
TRAIL treatments, the observations indicate that hCSCs
are more prone to TRAIL treatment after incubation with
PEITC. While the biological activity of PEITC in inducing
apoptosis of cancer cells may involve death receptor sig-
naling, other mechanisms have also been suggested
[12,13]. Finally, to investigate the antagonistic effects of
PEITC on hCSC tumorigenicity in vivo, we carried out
xenotransplantation in immune-compromised mice. Mice
receiving untreated hCSCs produced the highest numbers
of tumors and also showed greater invasiveness, as con-
firmed by the presence of lung metastases. However, given
the short 3-week duration of the experiment, metastasis
was found in only one of the four animals in the hCSC
group but in no other animal in the remaining groups.
We observed a marked reduction in tumorigenicity in
mice that had received a PEITC-treated hCSC inoculum,
and the outcome was comparable to the HeLa-injection
group. It should be noted here that the sphere culture ap-
proach to isolation of hCSCs that we used in the study
followed by cell-surface marker-based characterization
helps to identify CSC-enriched subpopulations but did
not enable unambiguous isolation of all of the CSCs.Conclusions
We have provided the first evidence that PEITC is
effective in abolishing human cervical CSCs in vitro,
and PEITC-treated hCSC xenotransplants were less
tumorigenic in a relevant mouse model. PEITC, in com-
bination with TRAIL, upregulated the death receptor-
induced extrinsic pathway of apoptosis and resulted in
the increase in cPARP proteins. It should be noted that
in the current study we did not evaluate the individual
effectiveness of TRAIL against hCSCs, but TRAIL is
currently in clinical trials in the US (NCT00508625).
Importantly, PEITC is anti-proliferative in both HeLa
cancer cells and hCSCs, suggesting that it may contrib-
ute to eradication of cancer more efficiently than com-
pounds targeting either CSCs or regular cancer cells
alone. Collectively, our data strongly justify future clin-
ical trials of PEITC, individually or in combination with
recombinant TRAIL therapy, for improved treatment
outcomes in cancer patients.
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